The European Commission has expanded its Ebola response with a €2.1 million purchase of PCR tests for the Bundibugyo virus outbreak. The agreement covers open-platform tests that laboratories can use with existing systems. Shipments are due to start in August as health teams confront a large outbreak centered in the Democratic Republic of the Congo and affecting parts of the wider region.

Australian researchers from Adelaide University and the Olivia Newton-John Cancer Research Institute have identified a novel molecular switch that drives the spread of aggressive tumors. Published in EMBO Molecular Medicine, the breakthrough study reveals that Australian researchers uncover a promising new way to tackle triple-negative breast cancer by restoring a critical regulatory molecule known as miR-342. The discovery opens new avenues to prevent life-threatening secondary cancers in organs such as the lungs and bones. Triple-negative breast cancer accounts for 10% to 15% of Australia’s approximately 21,000 annual breast cancer diagnoses but causes a disproportionate number of deaths. Lead investigators demonstrated that when miR-342 levels fall, a cancer-driving pathway called E2F becomes overactive, allowing dormant cancer cells to spread throughout the body and form dangerous secondary tumors. Diagnostic Biomarker Testing May Identify Patients Most Likely to Benefit In pre-clinical models, scientists demonstrated that restoring miR-342 levels markedly reduced the spread of cancer cells to distant organs. Furthermore, researchers discovered that palbociclib, an existing CDK4/6 inhibitor drug currently approved for hormone receptor-positive breast cancers, significantly halted metastatic tumor growth in models exhibiting low miR-342 levels. The findings suggest measuring miR-342 levels could allow doctors to repurpose existing therapeutics to treat high-risk patients. Co-senior author Associate Professor Philip Gregory from Adelaide University’s Centre for Cancer Biology confirmed that preventing metastasis remains the primary challenge in treating aggressive breast cancers. Gregory emphasized that

The International Coordinating Group on Vaccine Provision approved the release after the government requested doses from the global Ebola stockpile. WHO said 20,000 doses will support a Phase 3 clinical trial focused on Bundibugyo virus disease. The other 50,000 doses will go to frontline and health workers under current vaccination recommendations. WHO and Africa CDC welcomed the allocation, which officials announced on Aug. 20.

WHO incident manager Thierno Baldé said the three-month timeline depends on securing the resources required for the response. The agency has received about $69.3 million of the $115 million it says it needs, or roughly 60%. Teams added more than 400 treatment beds during the past two weeks. They also deployed 100 additional epidemiologists and more than 500 community health workers for surveillance and contact tracing. The response requires vehicles, ambulances, medical supplies and personnel across a growing affected area.

The Democratic Republic of the Congo recorded 26,064,143 malaria cases in 2025. The country also reported 29,938 deaths linked to the disease during the year. Guy Esebe Dembo, deputy director of the National Malaria Control Programme, announced the figures during a campaign launch in Ituri province. Dembo said malaria remains the country’s main public health challenge. The new totals confirm a heavy disease burden across one of Africa’s most malaria-affected countries.

DR Congo’s Ebola outbreak has killed 1,916 people and produced 4,209 confirmed cases, according to official data through Aug. 7. Ituri remains the center of the epidemic, with 3,636 confirmed cases and 1,551 deaths. North Kivu has recorded 470 cases and 315 deaths. Haut Uele has reported 91 cases and 44 deaths, while Tshopo has nine cases and five deaths. South Kivu has recorded three cases and one death. Overall, the outbreak has reached 53 of 140 health zones across the five affected provinces.